5 FDA Decisions for Primary Care to Know from April 2026

In April, the US Food and Drug Administration (FDA) issued several notable regulatory decisions spanning obesity management, infectious disease, rare genetic conditions, and diabetes care. The following list highlights 5 key updates for primary care, including approval of a novel oral GLP-1 receptor agonist for weight management, a new 2-drug regimen for virologically suppressed HIV, a first-in-class gene therapy for inherited hearing loss, and expanded use of automated insulin delivery technology in pregnancy.